Blood Sample + Cerebrospinal Fluid (CSF) Sample + Chemotherapy Drug, Cancer - Physician's Choice + Non-Investigational Surgical Resection + Radiotherapy (RT) + Tumor Tissue Sample + Temozolomide for neuroectodermal tumors, primitive

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Mar 2025: Trial registered, NCT06861244
  2. 6 Mar 2025: Trial started, NCT06861244

The trials

NCT06861244: Embryonal Tumor With Multilayered Rosettes

State
Under way
Phase
Phase 2
People
70 planned
Started
6 Mar 2025
Primary completion
30 Sep 2030
Arms
Cohort 1: Gross-total resection, non-metastatic, early radiotherapy, Cohort 2: Gross-total resection, non-metastatic, high-dose chemotherapy, Cohort 3A: Metastatic or residual disease, early radiotherapy, Cohort 3B: Metastatic or residual disease, high-dose chemotherapy
Results
None posted
  1. 6 Mar 2025: Trial registered
  2. 6 Mar 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.